West Nile Virus Encephalitis Victim's Family Wants to Increase Public Awareness of GenoMed's Clinical Trial
Thursday January 20, 9:30 am ET
ST. LOUIS, Jan. 20 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation DM(TM) (Disease Management) company which has been conducting a clinical trial against West Nile virus encephalitis for the past two summers, announced today that the family of Hazel Waldon, an 82 year old victim of West Nile virus encephalitis, is establishing a Memorial Fund to aid GenoMed's research.
ADVERTISEMENT
Ms. Waldon, who lived in southern California, went into a coma last August from which she never recovered. She died this past Sunday, January 16th. Last August her granddaughter spent three weeks searching the Internet for a treatment for West Nile virus encephalitis before finding GenoMed's clinical trial. By then her grandmother had already suffered a large stroke. GenoMed's approach was begun during the fourth week of coma, but it failed. It appears that the earlier a patient is begun on GenoMed's treatment, the more likely that full recovery can be achieved.
Said Ms. Waldon's granddaughter, "Despite her age, my grandmother was a very vigorous woman. Every Saturday morning she woke up at 5 a.m. to perform Bread Ministry, giving bread to the hungry. It's hard to believe a single mosquito bite could kill her. If I had known about GenoMed's clinical trial earlier, it's possible that she would still be alive."
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "I was extremely disappointed that we were unable to get Ms. Waldon out of coma. Now I'm overwhelmed by her family's generosity in supporting our research against West Nile virus encephalitis. With each patient we treat, we learn more. We now know that early treatment holds the best promise of success. For this, public awareness is key. The Internet and Google can't do it all; others have to help us get the word out."
About GenoMed
GenoMed is leading the clinical revolution which the Company's discovery of the major aging gene, ACE, has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. The Company is conducting numerous additional clinical trials, including ones for West Nile virus encephalitis and avian influenza, since inhibiting ACE may work as a broad- spectrum viral antidote. To enroll in one of GenoMed's free clinical trials, please email dwmoskowitz@genomed.com .
Midas |
